Options for managing psychotropic medications in drug-abusing patients participating in behavioral therapies clinical trials

American Journal on Addictions

Volumn 8, Issue 3, 1999, Pages 178-189

  Rounsaville, Bruce J ^a   Weiss, Roger ^b   Carroll, Kathleen ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BEHAVIOR THERAPY; CLINICAL RESEARCH; COMORBIDITY; DRUG ABUSE; DRUG DEPENDENCE; DRUG USE; HUMAN; PATIENT SELECTION; PRACTICE GUIDELINE; REPRODUCIBILITY; TREATMENT OUTCOME; VARIANCE;

BEHAVIOR THERAPY; HUMANS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SUBSTANCE-RELATED DISORDERS;

EID: 0032841662     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1080/105504999305794     Document Type: Article

References (65)

1. Chambless DL, Hollon SD. Defining empirically supported therapies. J Consult Clin Psychol. 1998;66:7-18.
2. Garfield SL. Some problems associated with "validated" forms of psychotherapy. Clin Psychol: Science and Practice. 1996;3:218-229.
3. Goldfried MR, Wolfe BE. Toward a more clinically valid approach to therapy research. J Consult Clin Psychol. 1998;66:143-150.
4. Seligman MEP. The effectiveness of psychotherapy: The Consumer Reports study. Am Psychol. 1995;50:956-974.
5. Ziedonis D, Fisher W. Motivation-based assessment and treatment of substance abuse in patients with schizophrenia. Directions in Psychiatry. Vol. 16, Lesson 11. New York, NY: Hatherleigh; 1996.
6. Najavits LM, Weiss RD, Liese BS. Group cognitive-behavioral therapy for women with PTSD and substance use disorder. J Subst Abuse Treat. 1996;13:13-22.
7. Hellerstein DJ, Meehan B. Outpatient group therapy for schizophrenic substance abusers. Am J Psychiatry. 1987;144:1337-1339.
8. Weiss RD, Najavits LM, Greenfield SF. A relapse prevention group for patients with bipolar and substance use disorders. J Subst Abuse Treat. In press.
9. Kessler RC, Nelson CB, McGonagle KA, Edlund MF, Frank RG, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization. Am J Orthopsychiatry. 1996;66:17-13.
10. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. The lifetime co-occurrences of DSM-III-R Alcohol Abuse and Dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997;54:313-321.
11. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 1990;264:2511-2518.
12. Ross HE, Glaser FB, Germanson T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry. 1988;45:1023-1031.
13. Rounsaville BJ, Kosten TT, Weissman MM, Kleber HD. Prognostic significance of psychiatric disorders in treated opiate addicts. Arch Gen Psychiatry. 1982;43:739-745.
14. Rounsaville BJ, Anton SF, Carroll K, Budde D, Prussoff BA, Gawin F. Psychiatric diagnosis of treatment-seeking cocaine abusers. Arch Gen Psychiatry. 1991;48:43-51.
15. Grant BF, Harford TC. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Drug Alcohol Depend. 1995;39:197-206.
16. Kranzler HR, Del Boca FK, Rounsaville BJ. Comorbid psychiatric diagnosis predicts three-year outcomes in alcoholics: a posttreatment natural history study. J Stud Alcohol. 1996;57:619-626.
17. McLellan AT, Luborsky LK, Woody GE, O'Brien CP, Druley KA. Predicting response to alcohol and drug abuse treatments. Arch Gen Psychiatry. 1983;40:620-625.
18. Rounsaville BJ, Weissman MM, Kleber HD, Wilber CH. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry. 1982; 39:161-166.
19. Rounsaville BJ, Dolinsky ZS, Babor TF, Meyer R. Psychopathology as a predictor of treatment outcome in alcoholics. Arch Gen Psychiatry. 1987; 44:505-513.
20. Woody GE, McLellan AT, Luborsky L, O'Brien CP. Sociopathy and psychotherapy outcome. Arch Gen Psychiatry. 1985;42:1081-1086.
21. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995;56:118-121.
22. Cornelius JR, Salloum IM, Cornelius MD, et al. Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacol Bull. 1995;31:297-303.
23. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry. 1994;51: 720-731.
24. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152:391-397.
25. Litten RZ, Allen JP. Pharmacotherapy for alcoholics with collateral depression or anxiety: an update of research findings. Exp Clin Psychopharmacol. 1995;3:87-93.
26. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996;275:761-767.
27. McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with primary depression. Arch Gen Psychiatry. 1996;53:232-240.
28. Nunes E, McGrath P, Quitkin F, et al. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry. 1993;150:963-965.
29. Nunes EV, McGrath PJ, Wager S, Quitkin FM. Lithium treatment for cocaine abusers with bipolar spectrum disorders. Am J Psychiatry. 1990;147: 655-657.
30. Nunes EV, Quitkin FM, Brady R, Stewart JW. Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry. 1991;148:667-669.
31. Olivera AA, Sarvis S, Heard C. Anxiety disorders coexisting with substance dependence: treatment with buspirone. Curr Ther Res. 1990;47:52-61.
32. Ziedonis DM, Kosten TR. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J Psychoactive Drugs. 1991;3:417-425.
33. Hughes Jr. Pharmacotherapy of nicotine dependence. In: Schuster CR, Kuhar MJ, eds. Pharmacological Aspects of Drug Dependence: Toward an Integrative Neurobehavioral Approach. New York, NY: Springer-Verlag; 1996:599-626.
34. Ling W, Charuvastra VC, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch Gen Psychiatry. 1976;33:709-720.
35. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881-887.
36. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone and the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
37. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337: 1195-1202.
38. Nunes EV, Quitkin FM, Donovan SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders: a placebo-controlled trial. Arch Gen Psychiatry. 1998;55:153-160.
39. Schubiner H, Tzelepis A, Isaacson JH, Warbasse LH, Zacharek M, Musial J. The dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review. J Clin Psychiatry. 1995;56:146-150.
40. Ciraulo DA, Sands DF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry. 1988;145:1501-1506.
41. Adinoff B. Long-term therapy with benzodiazienes despite alcohol dependence disorder. Am J Addict. 1992;147:288-293.
42. Allen JP, Litten RZ. Techniques to enhance compliance with disulfiram. Alcoholism Clin Exp Res. 1992;16:1035-1041.
43. Carroll KM, ed. Improving compliance with alcoholism treatment. Bethesda, Md.: National Institute on Alcohol Abuse and Alcoholism; 1997. NIH Publication 97-4143. NIAAA Project MATCH Monograph Series, Volume 6.
44. Weiss RR, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry. 1998;59:172-174.
45. Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction? In: Onken LS, Blaine JD, Boren JJ, eds. Integrating Behavioral Therapies with Medications in the Treatment of Drug Dependence. Rockville, Md.: National Institute on Drug Abuse; 1995;37-52. NIH publication 95-3899. NIDA Research Monograph Series No. 150.
46. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv. 1996;47:853-858.
47. Flick SN. Managing attrition in clinical research. Clin Psychol Rev. 1988;8:499-515.
48. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology. 1992;6:39-48.
49. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173-1182.
50. Gibbon RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analyses of longitudinal psychiatric data. Arch Gen Psychiatry. 1993;50:739-750.
51. Nich C, Carroll KM. Now you see it, now you don't: a practical demonstration of random regression versus traditional ANOVA models in the analysis of longitudinal follow-up data from a clinical trial. J Consult Clin Psychol. 1997;65:252-261.
52. Crits-Christoph P, Siqueland L, Blaine J, et al. The National Institute on Drug Abuse Collaborative Cocaine Treatment Study: rationale and methods. Arch Gen Psychiatry. 1997;54:721-726.
53. Kazdin AE. Research design in clinical psychology. 2nd ed. Boston, MA.: Allyn & Bacon; 1992.
54. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953-1959.
55. Carroll KM. Manual guided psychosocial treatment: a new virtual requirement for pharmacotherapy trials. Arch Gen Psychiatry. 1997;54:923-928.
56. Hargreaves W. Methadone dosage and duration for maintenance treatment. In: Cooper J, Altman B, Brown B, et al, eds. Research on the Treatment of Narcotic Addiction: State of the Art. Washington, DC: U.S. Government Printing Office;1983:19-91. DHHA publication ADM-83-1281. NIDA Treatment Research Monograph Series.
57. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag; 1991.
58. American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry. 1993;150(Suppl. 4):1-26.
59. Wei LJ. An application of an urn model to the design of sequential controlled clinical trials. J Am Stat Assoc. 1978;73:559-563.
60. Jacobson NS, Christensen A. Studying the effectiveness of psychotherapy: how well can clinical trials do the job? Am Psychol. 1996;51:1030-1039.
61. Onken LS, Blaine JD, Battjes R. Behavioral therapy research: a conceptualization of a process. In: Henggelen SW, Absentos. Innovative Approaches from Difficult to Treat Populations. Washington, DC: American Psychiatric Press; 1997:477-485.
62. Holder HD, Longabaugh R, Miller WR, Rubonis AV. The cost effectiveness of treatment for alcohol problems: a first approximation. J Stud Alcohol. 1991;52:517-540.
63. Carroll KM, Nich C, McLellan AT, McKay JR, Rounsaville BJ. "Research" versus "real world" patients: representativeness of subjects participating in clinical trial of treatments for cocaine dependence. Drug Alcohol Depend. In press.
64. McKay JR, Alterman AI, McLellan AT, Snider EC, O'Brien CP. Effect of random versus nonrandom assignment in a comparison of inpatient and day hospital rehabilitation for male alcoholics. J Consult Clin Psychol. 1995;63:70-78.
65. McKay JR, Alterman AI, McLellan AT, Boardman C, Mulvaney F, O'Brien CP. The effect of random versus nonrandom assignment in the evaluation of treatment for cocaine abusers. J Consult Clin Psychol. 1998;66:697-701.